Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vorinostat + bevacizumab + carboplatin + paclitaxel
- Development stage
- Phase 1
- Lead developer
- Merck
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
This is a four-drug combination regimen consisting of vorinostat, bevacizumab, carboplatin, and paclitaxel. - **Vorinostat** is a small molecule histone deacetylase (HDAC) inhibitor that modulates gene expression by altering chromatin structure, leading to cell cycle arrest and apoptosis in cancer cells. - **Bevacizumab** is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis required for tumor growth. - **Carboplatin** is a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis in rapidly dividing cells. - **Paclitaxel** is a microtubule-stabilizing agent that disrupts mitosis by preventing microtubule depolymerization, leading to cell death. This combination has been investigated primarily for the treatment of advanced solid tumors such as ovarian cancer and non-small cell lung cancer. The rationale for combining these agents lies in their complementary mechanisms—targeting epigenetic regulation (vorinostat), tumor vasculature (bevacizumab), DNA integrity (carboplatin), and mitotic spindle function (paclitaxel)—to maximize antitumor efficacy.
- Other names
- suberoylanilide hydroxamic acid
02
Targets
DNAHDAC1 (Histone Deacetylase 1)TUBB (Tubulin (alpha and beta subunits))VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on vorinostat + bevacizumab + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vorinostat + bevacizumab + carboplatin + paclitaxel.